Member Institution(s) Archives - Page 6 of 8

New Vaccine Research Aims to Prevent Recurrent Ear Infections

January 7, 2013 by BNMCin Homepage, Life Sciences Companies, Member Institution(s), News5 Comments

Lab in UB’s Clinical and Translational Research Center is one of few in the world studying an increasingly prevalent bacterium, once considered harmless
Children’s ear infections cause more than pain and sleepless nights; they temporarily disrupt hearing when children are at a critical age for speech and language development. They also have major social and economic costs.

But while infants and children receive immunizations against infections caused by Haemophilus influenzae and pneumococcus, there is no vaccine against Moraxella catarrhalis, an increasingly prevalent bacterium that causes at least ten percent of otitis media cases.

Now, University at Buffalo scientists, among just a handful of researchers in the world studying this organism, have received a $1.5 million National Institutes of Health (NIH) grant to develop a vaccine against it. The researchers are among the first tenants in UB’s Clinical and Translational Research Center, which opened in September on the Buffalo Niagara Medical Campus.

The goal of the current research, funded by the NIH’s National Institute on Deafness and Other Communication Disorders, is to identify new virulence mechanisms for this understudied pathogen, identify the structure of a candidate antigen for a new vaccine and develop a new vaccine.

According to Timothy F. Murphy, MD, SUNY Distinguished Professor of Medicine and Microbiology in the UB School of Medicine and Biomedical Sciences and principal investigator on the NIH grant, research on M. catarrhalis has lagged because it was originally believed to be a “commensal” or harmless bacterium. While it does cause milder cases of middle ear infections (otitis media) than other bacteria, Murphy said it is becoming more prevalent. Preliminary evidence also shows that existing ear infection vaccines are changing colonization patterns among otitis media pathogens, possibly increasing the prevalence of M. catarrhalis infections.

“Of the 15 to 20 million cases of otitis media each year in the U.S., about ten percent are recurring, causing incredible disruption for the child and the family,” explains Murphy. “When a child has the infection, the middle ear fills with fluid, a condition that can last for a month or longer. During that time, the child’s hearing is muffled, which disrupts the normal development of language and speech skills, potentially resulting in long term delays and learning problems in school.”

Recurrent ear infections also require repeated courses of antibiotics, which then contribute to the global problem of antibiotic resistance. Some children must undergo insertion of drainage tubes under general anesthesia.

“The best option would be to prevent these infections in the first place,” says Murphy.

The goal of the UB researchers is to identify M. catarrhalis antigens that are very similar among all strains so that a vaccine based on a single antigen will protect against as many strains of the bacterium as possible.

“Based on our results thus far, it looks like we will be able to identify antigens that are identical or very similar among all strains and genetic lineages,” says Murphy.

He and his colleagues are using bioinformatics to identify genes predicted to encode proteins on the surface of the organism, construct a gene chip to test which of more than 300 possible genes on the surface are identical or similar among multiple strains and then clone genes for some of the predicted proteins for testing in in vitro and mouse models.

The UB group is now testing several promising vaccine antigens that they have identified. A new vaccine could be ready for human testing in three to five years.

Murphy and his colleagues at UB are global leaders in the study of M. catarrhalis in otitis media in children and chronic obstructive pulmonary disease (COPD) exacerbations in adults. Their hope is that the same vaccine could be used to prevent both kinds of infections.

In addition to directing the M. catarrhalis research, Murphy directs UB’s Clinical and Translational Research Center and is senior associate dean for clinical and translational research in the UB medical school. For more than a decade, Murphy has studied how M. catarrhalis causes both otitis media in children and infections in chronic obstructive COPD in adults.

Ellen Goldbaum (UB); goldbaum@buffalo.edu; 716.645.4605

Molecule Inhibitor, CFAK-Y15, Could Treat Certain Brain Cancers

January 3, 2013 by BNMCin Homepage, Member Institution(s), Research2 Comments

Researchers from Roswell Park Cancer Institute (RPCI) have published findings from a preclinical study assessing the effectiveness of a small-molecule inhibitor, CFAK-Y15, in treating some brain cancers. The paper, published in Molecular Cancer Therapeutics, demonstrates for the first time that inhibiting the protein focal adhesion kinase (FAK) with CFAK-Y15 is an effective wp-contentroach to controlling growth of glioblastoma tumors, especially in combination with the standard chemotherapy agent temozolomide (Temodar).
FAK is overexpressed, or produced in excessive amounts, in tumor cells, and has been shown to play a key role in survival of cancer cells. In this study, a team led by Vita M. Golubovskaya, PhD, an Associate Professor of Oncology in the Department of Surgical Oncology, found that animal models treated with CFAK-Y15 demonstrated significantly prolonged survival compared to the control group. CFAK-Y15 provides FAK kinase-specific inhibition by upstream targeting of autophosphorylation sites on the FAK protein. It belongs to a class of ‘two for one’ compounds that also inhibit the oncoprotein Src by inhibiting its autophosphorylation.

“We found that CFAK-Y15 significantly decreased the viability of the glioblastoma cells, and in many cases wp-contenteared to cause tumor shrinkage — especially when CFAK-Y15 was given in combination with temozolomide,” noted Dr. Golubovskaya, the paper’s first author. “These compounds target FAK signaling, which is critical for cancer cell and cancer stem cell survival, especially in invasive and metastatic cancers.”

“We’re eager to see this research move to the clinical phase because of the great need for more effective treatments for glioblastoma,” noted senior author William G. Cance, MD, FACS, Surgeon-in-Chief and Chair of the Department of Surgical Oncology. “The potential impact is great because glioblastomas are such an aggressive tumor, and because we know they produce FAK in especially high quantities.”

The authors also included researchers from the University of California at San Diego and faculty from the Department of Pathology at RPCI. CFAK-Y15 is being developed by CureFAKtor Pharmaceuticals LLC (www.curefaktor.com). Drs. Cance and Golubovskaya, both of whom also serve on the management team of CureFAKtor, were part of the team that first identified CFAK-Y15, in research published in the Journal of Medicinal Chemistry in 2008.

The new abstract and paper, “Pharmacological blockade of FAK autophosphorylation decreases human glioblastoma tumor growth and synergizes with temozolomide,” can be accessed online at http://mct.aacrjournals.org/content/early/2012/12/12/1535-7163.MCT-12-0701.

This work was supported by Susan Komen for the Cure Foundation grant BCTR0707148 and three National Cancer Institute (NCI) grants: R01CA065910, R01HL073396, and the NCI’s Cancer Center Support Grant for Roswell Park Cancer Institute (P30CA016056).

Annie Deck-Miller, RPCI Senior Media Relations Manager; annie.deck-miller@roswellpark.org; 716-845-8593

New Center of Excellence Tenant's Research to Help Treat Muscular Dystrophy

December 20, 2012 by BNMCin Community, Homepage, Life Sciences Companies, Member Institution(s), News, Research4 Comments

Inspired by his grandson, JB’s Duchenne muscular dystrophy diagnosis, Jeff Harvey, Tonus Therapeutics co-founder and chief financial officer, along with Frederick Sachs, University at Buffalo (UB) Distinguished Professor, Thomas Suchyna, Research Assistant Professor, and Philip Gottlieb, Research Associate Professor, all from UB’s Department of Physiology and Biophysics, partnered to develop a therapy for muscular dystrophy. Establishing Tonus Therapeutics in 2009, the group began to work together based off of initial research Sachs and his team first came across nearly 10 years ago, studying the effect of venoms on mechanosensitive ion channels.
As one of several forms of muscular dystrophy, Duchenne is the most lethal, rapidly getting worse over time causing respiratory problems in addition to severe and increased limb-muscle weakness. The absence of the dystrophin protein is due to a defective gene commonly found in males. Dystrophin helps muscle cells maintain their shape structure. Without that protein, cell membranes tear apart more easily and cause the muscle to contract abnormally. According to Sachs, when this hwp-contentens, the body “starts digesting muscle from the inside out.”

A UB spin-off company, having made the New York State Center of Excellence in Bioinformatics & Life Sciences (CoE) its home headquarters, Tonus Therapeutics will continue its quest to develop drugs that help distribute and control the transfer of mineral substances like calcium to cells through the tiny conduits known as mechanosensitive ion channels. These channels, which Sachs co-discovered in 1983, connect the inside of a cell with its outside. Normally, in healthy cells the channels are closed, but when a cell is stretched or contorted, the channels open and let calcium and other substances into the cell.

Using GsMTx4, a peptide that scientists at UB discovered in the venom of the Chilean rose tarantula, Tonus Therapeutics will use the FDA “orphan drug” designation to move forward with the development of a therapy for muscular dystrophy. The designation of GsMTx4 comes with recognition from the government agency that the peptide is a promising method of treatment for a rare disease like muscular dystrophy. Research shows that GsMTx4 is capable of staying in the body for a long time without breaking down. This means it could be possible to deliver low doses infrequently, reducing costs for patients. The company has gathered preliminary data showing that GsMTx4 is nontoxic in mice and did not disturb heart function in mice or ferrets or isolated human heart muscle.

In November, Tonus Therapeutics licensed UB patents relating to GsMTx4 through UB’s Office of Science, Technology Transfer and Economic Outreach (UB STOR).

Harvey stated that “Being located in a hub of research activity in Buffalo, close to other entrepreneurs and biotech startups, is important to [Tonus Therapeutics].” He also stated that “The Buffalo Niagara Medical Campus is extremely important to us because it provides ready contact with experienced entrepreneurs and potential clinical and commercial partners, including those within the [CoE].”

The CoE, a part of the 400,000 sq. ft. Buffalo Life Sciences Complex, houses more than 100 scientists with biological, physical and computational expertise. The CoE’s efforts aims to leverage its research resources, helping to create new technological advantages for health care and life sciences industry sectors, partnering with and supporting biomedical, research and development companies like Tonus Therapeutics. Marnie LaVigne, UB associate vice president for economic development stated that “Tonus benefits from the technological and business resources available here, and their continued growth will be an asset to Western New York’s economy.”

Prior to their move into the CoE, the Tonus team benefited from other UB resources and partnerships. Harvey is a graduate of the UB School of Management’s High-Tech Center for Entrepreneurial Leadership program, and Tonus received funding through the UB Center for Advanced Biomedical and Bioengineering Technology (UB CAT). The Children’s Guild Foundation and the John R. Oishei Foundation have provided additional funding.

Learn more about Tonus Therapeutics below:

Roswell Park Recognizes Staff, Community Supporters at 5th Annual Eva M. Noles Progra

December 13, 2012 by BNMCin Community, Event, Member Institution(s), News6 Comments

FOR IMMEDIATE RELEASEDecember 12, 2012
Contact: Annie Deck-Miller, Senior Media Relations Manager
716-845-8593; annie.deck-miller@roswellpark.org

Roswell Park Recognizes Staff, Community Supporters at 5th Annual Eva M. Noles Program
Scholarship awarded to RPCI employee in tribute to Buffalo’s first African-American nurse

BUFFALO, NY — DeMarco Ogletree, a cashier in the Nutrition & Food Service Department at Roswell Park Cancer Institute (RPCI), earned the $2,000 Eva M. Noles Scholarship Friday, December 7 at the fifth annual Eva M. Noles Scholarship and Community Recognition Breakfast at RPCI. The annual program honors the legacy of Eva M. Noles, RN, Buffalo’s first African-American registered nurse and a longtime RPCI employee who served in many leadership roles at the Institute, including as Director of Nursing.

Ogletree joined the Roswell Park staff in the spring of 2012. He is presently pursuing degrees in both nursing and theology at Erie Community College and plans to continue his work in healthcare, helping to fight health disparities in the Buffalo area. “From his first days with us, DeMarco has committed himself wholeheartedly to the Roswell Park mission,” said David Scott, RPCI Director of Diversity and Inclusion. “He has contributed greatly as an employee, and now we have a great opportunity to reward that commitment — which embodies the work, spirit and legacy of Ms. Noles — and help him achieve his career goals by providing a scholarship toward his studies.”

Darius G. Pridgen, Pastor of True Bethel Baptist Church in Buffalo and Ellicott District Councilmember for the City of Buffalo, gave the keynote address at the program, during which several RPCI staff members and volunteers were recognized for their role in providing cancer education and preventive outreach to underserved communities throughout Western New York. Among those recognized were Georganne Alexander, a volunteer with the Buffalo/Niagara Witness Project; Ramon Luciano Jr., a volunteer with Minorities Allied for the Need to Understand Prostate Cancer (MAN UP); Carmen Sepulvedad, a volunteer with the Esperanza y Vida Project; and Gloria Quarles, a volunteer who serves on Roswell Park’s Community Advisory Steering Committee.

Staff and volunteers were also recognized for their contributions to Cruisin’ for a Cure, a prostate cancer education and screening event held at RPCI in September, and to the African American Roswell Employee Network, whose activities include year-round community outreach on behalf of RPCI.

The mission of Roswell Park Cancer Institute (RPCI) is to understand, prevent and cure cancer. RPCI, founded in 1898, was one of the first cancer centers in the country to be named a National Cancer Institute-designated comprehensive cancer center and remains the only facility with this designation in Upstate New York. The Institute is a member of the prestigious National Comprehensive Cancer Network, an alliance of the nation’s leading cancer centers; maintains affiliate sites; and is a partner in national and international collaborative programs. For more information, visit RPCI’s website at http://www.roswellpark.org, call 1-877-ASK-RPCI (1-877-275-7724) or email askrpci@roswellpark.org.

Research from UB and Immco Diagnostics Leads to Early Detection of Sjogren’s Syndrome

December 13, 2012 by BNMCin Homepage, Member Institution(s), News, Research4 Comments

Patients suffering from the painful autoimmune disease, Sjogren’s Syndrome, will soon be able to be properly diagnosed much earlier, thanks to the discovery of novel antibodies by researchers at the University at Buffalo (UB) and Immco Diagnostics, Inc. The breakthrough, described in a paper in the December issue of Clinical Immunology, will allow patients to be treated sooner when they are much more likely to benefit. The new diagnostic test will be available to physicians in early 2013.
“Sjogren’s patients get diagnosed too late,” says Julian L. Ambrus Jr., MD, professor in the Department of Medicine in the UB School of Medicine and Biomedical Sciences, an immunologist at Buffalo General Medical Center and senior author on the paper. “They go to the doctor because their eyes are dry or they can’t swallow, but by that time, their salivary or tear glands are already dead. They’re way past the point where they can generally benefit from any treatment.”

The new antibodies were seen in 45 percent of patients who met most of the clinical criteria for Sjogren’s except for the antibodies currently required for diagnosis, called Ro and La. At least one of the novel antibodies is present in 76 percent of patients who have had symptoms for less than two years and who also lacked the two antibodies required for definitive diagnosis, which wp-contentear late in the disease.

“The vast majority of patients we tested who have early symptoms of severe dry mouth and dry eyes also have these antibodies,” says Ambrus.

The journal highlighted the research paper with an editorial by Robert I. Fox, MD, PhD, of Scripps/Ximed, considered one of the world’s top Sjogren’s Syndrome scientists.

Considered one of the three most common autoimmune diseases, Sjogren’s Syndrome affects more than 4 million Americans, 90 percent of them women; last year, Venus Williams, the tennis champion, announced that she had the disease. Symptoms are dry eyes and dry mouth so severe that they are painful. Despite its high incidence, Sjogren’s is not well-known and can take years to diagnose; once diagnosed, it is often too late to effectively treat it.

Beyond the chronic pain associated with not being able to produce tears or saliva, the disease is associated with additional, systemic consequences, such as mild kidney and lung disease. Five to 10 percent of Sjogren’s patients also will develop lymphoma, cancer of the lymphocytes, a type of white blood cell that is continually produced in Sjogren’s Syndrome.

The discovery of novel antibodies grew out of a strong collaboration between UB and Immco, which in 2006 resulted in a new, far superior animal model for Sjogren’s Syndrome.

“Our animal model has completely changed how people think about this disease,” says Ambrus. “Sjogren’s disease in our animal model marches along in exactly the same way that the human disease does, reproducing every stage of the disease.”

Labs studying Sjogren’s around the world have now adopted the new model developed at UB and Immco, which is based in Amherst.

Once the new antibodies were detected in mice, the scientists started testing human patients at Buffalo General Medical Center. The researchers found the same antibodies in humans even at early stages of the disease.

UB has filed a patent on the biomarker-based method and licensed the technology to Immco, which has developed a new diagnostic tool based on the research.

“We believe this is one of the most undiagnosed autoimmune diseases,” says William Maggio, Immco’s chief executive officer.

The new diagnostic tool his company developed for Sjogren’s Syndrome has significant proprietary value. “We will be the only company in the world to offer and market this test across any platform,” he says.

And because Sjogren’s Syndrome presents with various symptoms, unlike other autoimmune diseases, this diagnostic test will be marketed to several different types of physicians, including dentists, oral surgeons, ophthalmologists and rheumatologists.

The assay will undergo validation by the New York State Department of Health. Once complete early next year, physicians will be able to start using the test. Patient samples from around the nation will be sent to Immco for testing. Immco also is developing a diagnostic kit for customers to be marketed internationally.

“If the market is as successful as we anticipate, then it will lead to more employment opportunities locally,” says Maggio.

Already, the UB and Immco scientists have begun collaborating with several international groups working on Sjogren’s Syndrome, giving them access to many more patients.

“Sjogren’s patients are miserable,” says Lakshmanan Suresh, DDS, vice president, research and development at Immco and clinical associate professor in the Department of Oral Diagnostic Sciences in the UB School of Dental Medicine. “They cannot taste anything, they often have serious tooth decay, and they feel as though they have sandpaper or grit in their eyes all the time. If we can find the antibodies early, then we can start to develop therapies to target them. The first step though, is to make the diagnosis.”

“This is a very good example of how research and industry collaborate to produce something that will bring a lot of good to the health-care industry and it’s hwp-contentening here in Buffalo,” says Maggio.

The UB researchers recently received a $450,000 grant from the National Institutes of Health to study how the immune system becomes dysfunctional in Sjogren’s disease.

Last summer, the project also received funding from UB’s Center for Advanced Biomedical and Bioengineering Technology, one of 15 centers across New York State funded by the Empire State Development’s Division of Science, Technology and Innovation to support university-industry collaboration in research, education and technology transfer.

Along with Ambrus, Shen and Suresh, co-authors on the Clinical Immunology paper are Jingxiu Xuan, PhD, research assistant professor in the UB Department of Medicine and Matthew Lindemann, PhD, director of assay development, Przemek Kowal, PhD, director of biopolymers, and Kishore Malyavantham, PhD, director of scientific initiatives, all from Immco.

Ellen Goldbaum (UB); goldbaum@buffalo.edu; 716.645.4605

RPCI Receives Leapfrog Top Hospital Recognition for 3rd Straight Year

December 4, 2012 by BNMCin Homepage, Member Institution(s), News6 Comments

Roswell Park Cancer Institute (RPCI) has been named to The Leapfrog Group’s annual Top Hospitals list for a third consecutive year. One of only three National Cancer Institute-designated comprehensive cancer centers in New York state, RPCI is the only New York facility to be named a Leapfrog Top Hospital for 2012.
The Leapfrog Top Hospital designation puts RPCI in a class representing less than 8% of eligible hospitals. In all, 67 urban facilities, 13 rural institutions and 12 children’s hospitals earned the designation this year. The Leapfrog Group, a coalition of public and private employers, selects hospitals for the designation based on an annual national survey measuring performance in areas such as error prevention, Intensive Care Unit staffing and complex, high-risk procedures.

“The Leapfrog Top Hospital distinction is by far the most competitive award a hospital can receive. Leapfrog holds hospitals to the highest standards on behalf of our purchaser members and their employees,” said Leah Binder, President & CEO of The Leapfrog Group. “By achieving the Top Hospital accolade, Roswell Park Cancer Institute has demonstrated exemplary performance across all areas of quality and patient safety that are analyzed on the Leapfrog Hospital Survey. This hospital stands out as one consistently providing safe, high quality care, and I would be comfortable sending my family to Roswell Park for care.”

RPCI has frequently been recognized for high-quality care and overall excellence. The Institute was again recognized in U.S. News & World Report’s 2012-13 Best Hospitals list for Cancer Care and also this year was re-certified for a three-year period by the Joint Commission, an independent accrediting body.

“We are extremely proud to receive the Leapfrog award for the third consecutive year. Roswell Park participates in a number of quality assessment programs every year — many of them, like the annual Leapfrog survey, on a voluntary basis,” said Roswell Park Medical Director Judy Smith, MD. “Through this process we can evaluate the work we do and look for opportunities for further improvement; it is an invaluable opportunity for a thorough, unbiased review by an informed outside organization.”

Annie Deck-Miller; annie.deck-miller@roswellpark.org; 716-845-8593

State and Private Sector Investment on BNMC to Create 250 Jobs for Region

December 4, 2012 by BNMCin Campus-wide, Investment Opportunities, Life Sciences Companies, Member Institution(s), News5 Comments

Today, Governor Andrew Cuomo announced that New York will invest $50 million in state of the art biomedical research equipment and facilities, and has secured an agreement from a private company, Albany Molecular Research Inc. (AMRI), to locate on the Buffalo Niagara Medical Campus a new drug discovery research and development center. This investment, $35 million of which will go towards new equipment and $15 million of which will go towards improving existing lab space, will leverage $200 million in private investments and create 250 jobs. More details on this development as well as the Buffalo Billion Investment Development Plan can be found here. http://www.governor.ny.gov/press/12042012-buffalo-billion-investment-plan.
Wondering how this investment model really works? Fahreed Zakaria from CNN’s “Global Lessons: Putting America to Work” recently highlighted how this model was successful in Albany, where New York State invested in core infrastructure and equipment as an incentive to attract private sector companies. Watch the video here – http://www.cnse.albany.edu/Files/Downloads/Video%20Clips/CNNGlobalCrisp6.mov.

Read coverage about the announcement below:

Announcements show Cuomo’s commitment to WNY

Cuomo, $50 million bring Albany firm, 250 jobs to Medical Campus

Cuomo Touts Drug Company’s 250 Jobs for Medical Campus

$50M biomedical facility planned for Buffalo

BHSC's Therapeutic Playground Opens for Children with the Support of Donors

November 19, 2012 by BNMCin Homepage, Member Institution(s), News5 Comments

Left to right: Joe Cozzo, President & CEO, Buffalo Hearing & Speech Center; Alexandra Wehr, Sr. Relationship Manager, KeyBank, Marie Hare, Vice President of Community Affairs, KeyBank, and Gary Quenneville, President (Western New York District), KeyBank.

Buffalo Hearing & Speech Center (BHSC) installed a new therapeutic playground after 2 years of planning and months of construction. The playground project received a supportive boost by the KeyBank Foundation. Additional support came from the Buffalo Sabres Foundation, the Rotary Club of Buffalo, the DreamCatcher Foundation, the Buffalo Bills Youth Foundation and nearly 100 other individual donors from the Western New York community.

Located at 50 East North Street on the Buffalo Niagara Medical Campus, the playground will help to stimulate the senses of the more than 200 children who attend the school. BHSC provides innovative programs and cutting edge capabilities aiding in the diagnosis and treatment of communication disorders, literacy, autism, and learning challenges.

The playground was designed by a team of physical and occupational therapists with the goal of having each piece on the playground help to meet the diverse needs of the students at BHSC in need of speech, hearing or educational services. The therapeutic playground structure consists of a large multicolored play system built on a safe rubberized surface that can accommodate the different needs of students. The new playground offers a cohesive, natural environment where children are content and comfortable while they develop social skills at a level wp-contentropriate for them. The playground offers multiple varieties of sensory play experience so that children of all abilities are able to play and learn. By supporting the sensory needs of all children, the playground enhances individual development in ways that cannot be achieved by standard methods.

Every day, students at the BHSC learn, grow, and have fun while on the campus grounds. “Play is a very important part of the childhood experience. Buffalo Hearing & Speech Center recognizes that that act of playing is where children are able to explore, discover, create and imagine, while learning about the world around them firsthand,” said Jospeh Cozzo, President and CEO of the BHSC.

BHSC offers audiology, early childhood, speech language, and pathology services, in addition to a number of specialized programs for children and adults. Learn more about BHSC:

UB Purchases First Properties for School of Medicine and Biomedical Sciences

November 15, 2012 by BNMCin Homepage, Member Institution(s), News1 Comment

UB Takes Historic First Step to Acquire Downtown Buffalo Properties on which New Medical School will be Built

The University at Buffalo today announced the purchase of land at 960 Washington St., the first of several parcels it is assembling to make way for construction of the new $375 million University at Buffalo School of Medicine and Biomedical Sciences.

The lot is one of three properties, located in the Main/High streets area, which UB hopes to acquire by the end of the year for its historic project to relocate the medical school from the UB South Campus to the downtown Buffalo Niagara Medical Campus.

“In moving our medical school downtown, where it will be ideally aligned with local hospitals and other key life sciences partners, UB is staying true to our roots in more ways than one,” said UB President Satish K. Tripathi.

“Building healthier communities has always been a vital focus of our academic mission — from our early days as a small private medical school serving the City of Buffalo in the 19th century, to our 21st century role as a major public research university that enriches the quality of life both locally and globally. The acquisition of this land is a timely and important next step as we move forward with this critical next phase of UB 2020.”

UB planners have selected HOK to design the state-of-the-art medical school and biomedical sciences center. Ground will be broken for the new UB facility in September 2013. One of the world’s leading architectural firms, HOK has a global portfolio of health sciences facilities and academic buildings and an international reputation for sustainable design.

The $375 million project, funded in part by NYSUNY 2020 legislation signed into law last year by Gov. Andrew M. Cuomo, is a key component of the UB 2020 plan for academic excellence, which is intended to benefit students, faculty, staff and the Western New York community. The new medical school will sit at the corner of High and Main streets, in the center of the region’s emerging biosciences corridor, a short walk from hospitals, research centers and incubators that nurture new bioscience start-up companies.

The acquisition was executed by UB Foundation Services Inc. (UBFS).

“This is an exciting step in an effort to create a world-class medical school on the Buffalo Niagara Medical Campus. We are proud to facilitate this purchase on behalf of the university and its medical school,” said Robert Denning, chairman of the UBFS board.

UBFS paid $1.2 million to acquire the parcel from Evergreen Real Estate, whose partners are developer Michael Joseph and businessman Kevin Brinkworth, which has owned the property since 2005. Real estate firm CBRE Buffalo worked with the UBFS to broker the property transaction.

The University at Buffalo Foundation noted that Joseph served on its board from 2002 through 2008, prior to when UB began contemplating relocation of its medical school to the downtown site.

FNUB Inc, an affiliate of the University at Buffalo Foundation, is continuing negotiations on other properties to accommodate the first phase of the medical school project. Separate discussions continue between UB and the Niagara Frontier Transportation Authority regarding the Main-Allen Transit station, which the university would like to incorporate into the medical school building.

John DellaContrada; dellacon@buffalo.edu; 716-645-4601

RPCI Completes Phase 1 for Development of Clinical Sciences Center with New Era Donation

November 8, 2012 by BNMCin Fundraiser, Homepage, Member Institution(s), News3 Comments

With the help of a recent $1.5 million donation from New Era, Roswell Park Cancer Institute‘s (RPCI) Clinical Sciences Center (CSC) has reached its Phase 1 development goal.
The Making Room to Save Lives: The Campaign to Build a Greater Roswell Park is a result of RPCI’s growing patient population. Since the campaign began back in June 2011, it received a $10 million donation from Circle of 10 – a collaborative gift from 10 well known business and philanthropic leaders in Western New York. RPCI patients even gave a $1 million gift that was included in the initial gift of $10 million. A total of 435 donors contributed to Phase I of the Making Room to Save Lives campaign.

The 11-story, 142,000 sq. ft. CSC to be built on Michigan Avenue and Carlton Street will literally make room for the increasing need for cancer services offered at one of the nation’s leading cancer centers.

RPCI’s President and CEO, Donald L. Trump, MD, FACP, stated that “Over the past five years, we have seen a nearly 40% increase in patients and we have seen an almost 60% rise in outpatient wp-contentointments over the past decade.” New Era’s gift has made the process involved with meeting the needs of patients more tangible.

Connected to the main RPCI entrance, the CSC will serve as the location for patients to be screened for cancer and manage outpatient treatments. Its administrative offices will also operate out of the builing. Within the CSC will be a new Chemo-Infusion Clinic that will be twice as large as the present clinic; a Breast Center that will offer community mammography services; a new Mammography Center; an Adolescent and Young Adult Clinic; and a Patient Education/Survivorship Center for RPCI’s patients and their families. The CSC will have additional state-of-the-art office facilities and space for clinician-scientists to analyze data from clinical studies.

A supporter of cancer research, prevention and education as one of its four key platforms, New Era’s gift to Roswell Park continues a long tradition of philanthropy.

“At New Era, we strongly believe in giving back to the communities that we work and live in. One important way we do this is by engaging in partnerships and signature programs that focus on finding a cure for cancer,” said Christopher Koch, CEO of New Era.

The Roswell Park Alliance Foundation raised $40 million for Phase 1 to begin the process of building the CSC. Construction for Phase I is scheduled to begin in Spring 2013. An additional $10 million will be raised in Phase II for the Center’s “build out” and shell space requirements.

Rendering by FxFOWLE Architects

November = Lung Cancer Awareness Month

November 6, 2012 by BNMCin Campus-wide, Community, Environment, Homepage, Member Institution(s), News, Wellness6 Comments

It is natural to think of family, food and the things one is most thankful for when November rolls around. Raising awareness for lung cancer during the month of November is important to think about as well. While only 1 out of every 10 smokers will get lung cancer, it is still the number 1 cancer killer of men and women in the country, killing nearly 150,000 people per year. It is the second-most diagnosed cancer in men and women as well.
Its cause: smoke inhalation. Smoking tobacco or any kind of drug is the highest risk factor for lung cancer. Secondhand smoke causes nearly 50,000 deaths of nonsmokers every year according to the U.S. Department of Health and Human Services. Lung cancer has increasingly become a disease that is not just associated with smokers. Other risk factors include exposure to radon, asbestos, polluted air, and an existing lung disease.

According to Roswell Park Cancer Institute (RPCI) Associate Professor of Oncology and Director of Collaborative Research in the Department of Medicine, Mary Reid, PhD, between 60% and 70% of patients with lung cancer are diagnosed too late, making surgery a non-option. As efforts increase to create more early screening options, the probability of prolonging life increases dramatically.

RPCI Lung Cancer Screening

Through its High-Risk Lung Cancer Program, RPCI offers lung cancer screening for those who meet the criteria below:

Previously treated lung, oral, throat and/or esophageal cancer
Smoking more than a pack of cigarettes a day for at least 20 years or the equivalent
Chronic lung disease, such as emphysema, chronic bronchitis or chronic obstructive lung disease (COPD)
Occupational-related asbestos disease
A family history of lung cancer in a first-degree relative
History of substantial secondhand smoke exposure

Tests used to detect lung cancer in its early stages are Bronchoscopy and Low-Dose Chest CT Scan (LDCT).

RPCI Lung Cancer Treatment

The Thoracic Lung Cancer Center at RPCI offers specialized comprehensive care for the prevention, diagnosis and treatment of lung cancer. Lung cancer patients treated at the Thoracic Center receive the the latest and most efficient treatment and surgical procedures, including Video Assisted Thoracic Surgery (VATS). VATS is a minimally invasive surgery that enables the surgeon to remove tumors in openings no bigger than 1-inch in diameter using a small video camera.

Cessation Programs

The New York State Smokers’ Quitline is free and confidential. Services include telephone counseling, a starter kit of free nicotine replacement, medications for eligible smokers, access and referrals to local smoking cessation programs and more.

RPCI offers a smoking cessation program, Just Breathe, helping smokers to quit using customized plans, in addition to providing behavioral counseling, and pharmacotherapy.

Learn more about lung cancer on RPCI’s website.

RPCI’s Mary Reid, PhD

Glick Receives National Editorial Award for Third Consecutive Year

November 5, 2012 by BNMCin Member Institution(s), News4 Comments

For release: November 5, 2012Sara R. Saldi; saldi@buffalo.edu
University at Buffalo
716-645-4593

Glick Receives National Editorial Award for Third Consecutive Year

BUFFALO, N.Y. — Michael Glick, DMD, professor and dean of the University at Buffalo School of Dental Medicine, has been awarded the American Dental Education Association’s (AADE) William J. Gies Foundation First Place Editorial award for the third year in a row. The presentation of the award was made during the annual meeting of the American Association of Dental Editors (AADE) Oct. 17 in San Francisco.

A photo of Glick is available at: http://www.buffalo.edu/news/13782.

Since 1958 the William J. Gies Editorial Award has been presented yearly to the author of the most valuable editorial published in a dental journal or periodical. The AADE and the William J. Gies Foundation for the Advancement of Dentistry of the American Dental Education Association (ADEA Gies Foundation) collaborate each year to identify and recognize award recipients.

Glick received the 2012 award for his editorial in the Journal of the American Dental Association (JADA): “Clinical Judgment: A Requirement for Professional Identity.” He won the same award in 2011 for his JADA editorial, “Education and Training: Two Different Proficiencies Necessary to Provide Oral Health Care” and in 2010 for a JADA editorial, “Expanding the Dentist’s Role in Health Care Delivery: Is it time to discard the Procrustean bed?”

The award is named for William J. Gies, a biochemistry professor from Columbia University who, in 1926, published a landmark report on dental education in the U.S. and Canada. Each year, dental editors from across the country submit their best editorials to be considered for the award. The editorials are reviewed by the William J. Gies Foundation Editorial Award Judging Committee, which makes the selection.

Glick, who became UB dean in December 2009, is editor of JADA, the premier, peer-reviewed journal in dentistry. Glick is known for his innovative, medicine-oriented wp-contentroach to dental care; he is an advocate for having dental students think of themselves as health care professionals first, and dentists second.

This is the fourth year in a row that a faculty member from UB’s School of Dental Medicine has won the award. In addition to Glick’s awards in 2010 and 2011, Chester J. Gary, DDS, JD, clinical assistant professor in restorative dentistry, was the recipient in 2009.

Glick has published more than 200 articles, book chapters and monographs on topics related to oral medicine. He has also led the way in the area of clinical dental care for medically complex patients, including those with HIV. He is a proponent for dentists to become involved in the overall health and well-being of their patients, which may include chair-side screening of dental patients for cardiovascular disease and other chronic illnesses.

WCHOB and RPCI Partner to Create New Pediatric Hematology Oncology Center

November 1, 2012 by BNMCin Health care, Member Institution(s), News8 Comments

Continuing efforts to create a multifaceted children’s hospital, Kaleida Health‘s Women & Children’s Hospital of Buffalo (WCHOB) and Roswell Park Cancer Institute (RPCI) have partnered to build a pediatric hematology oncology center in the new John R. Oishei Children’s Hospital.
Signing a memorandum of understanding to plan the new center today, the WCHOB and RPCI have begun the planning process for this physician-led initiative to combine their services, creating a single center of excellence for pediatric inpatient/outpatient care. The proposed Center will incorporate inpatient beds, an outpatient clinic, isolation beds for blood and bone marrow transplant/high-dose therapy patients, and infusion facilities for chemotherapy and blood products, all in a protected environment on the top floor of the new hospital.

Both institutions are two of the most prominent healthcare institutions in WNY, providing pediatric hematology-oncology services for more than forty years. Currently, WCHOB provides specialty pediatric services essential to the care of these children including surgery, anesthesia, intensive care, and diagnostic imaging. RPCI provides oncology clinical leadership and services including radiation therapy, certain highly-specialized diagnostic services, blood and marrow transplants and clinical trials. RPCI is expected hold a long-term lease for the Center and will be responsible for its medical direction. The planned Center will continue to capitalize on the unique expertise of both institutions.

“This partnership between the two organizations is an excellent example of the many opportunities the new John R. Oishei Children’s Hospital on the Buffalo Niagara Medical Campus is granting,” said Teresa Quattrin, MD, Chair, Department of Pediatrics, Professor of Pediatrics, SUNY at Buffalo, and Pediatrician-in-Chief, Chief, Division of Endocrinology-Diabetes, Women & Children’s Hospital of Buffalo. “We look forward to continuing to create this integrated Hematology & Oncology Unit to further enhance the care provided to patients and their families throughout Western New York and beyond.”

WCHOB is submitting its Certificate of Need wp-contentlication for the new hospital to the New York State Department of Health on November 2nd. RPCI anticipates to submit the Certificate of Need for the Pediatric Hematology Oncology Center by the end of the year.

“Each institution contributes unique expertise and services to children and young adults with cancer and blood disorders such as sickle cell disease, hemophilia and anemia. The new hospital presents a great opportunity to develop a true pediatric Center of Excellence,” said Martin L. Brecher, MD, Chair of Pediatrics at Roswell Park Cancer Institute, Chief of Hematology Oncology at Women & Children’s Hospital and Chief of Pediatric Hematology-Oncology in the Department of Pediatrics at the University at Buffalo.

James R. Kaskie, President and CEO of Kaleida Health stated that “Together, and in conjunction with the University at Buffalo academic programs, we will jointly operate a center of excellence for children with cancer and blood diseases where expert clinical services are provided, innovative and pioneering research is advanced to find a cure and improve treatment options, and current and future health care professionals are trained and educated.”

“Management of cancer is best provided in facilities where hospital inpatient beds and outpatient facilities are in close proximity. The relocation of the children’s hospital to the medical campus provides the opportunity to pull together what have been two physically separate outpatient and inpatient units into a single, expanded service comprehensive facility to serve the needs of children of all ages with blood diseases and cancer,” said Donald L. Trump, MD, President and CEO of RPCI.

Each institution’s respective Board of Directors recognizes that the relocation of the WCHOB to the BNMC presents a unique opportunity to take an excellent pediatric hematology oncology program and make it extraordinary by bringing all the services together in a new state-of-the-art hospital. Philanthropic support for the hospital and for the pediatric hematology oncology center will be required to make the program consolidation a reality.

The 12-story, 430,000 sq. ft. John R. Oishei Children’s Hospital is scheduled to open in 2016.

BNMC Partners and Fruit Belt Residents Embark on Leadership Empowerment Program

October 29, 2012 by BNMCin Community, Fruit Belt, Healthy Communities, Member Institution(s), News, Outreach7 Comments

Members of the Fruit Belt neighborhood will begin leadership training that will ignite change within their community. These leaders will participate in an eight week course in which they will identify and create change in pursuit of increasing their quality of life. Led by a coalition of BNMC Partners, such as the University at Buffalo (UB), with other BNMC member institutions; Roswell Park Cancer Institute and Kaleida Health, the training provided by the UB School of Management and Leadership Buffalo will teach the group how to identify the most prevalent issues, build a plan to address each issue, and measure their success.
A kick-off event for the training will occur Wednesday, November 7th (rescheduled from Tuesday, October 30th) starting at 5:00 p.m. at Roswell Park Cancer Institute’s Gaylord Cary Meeting Room in the Research Studies Center on Carlton Street. Group participants will convene with Council member Darius Pridgen to meet the mentors, the leadership trainer, institution representatives and become acquainted with one another as they prepare to embark on the four-month long journey to impact their community.

The expert training will also prepare the group with strategies on how to take advantage of collaboration opportunities with BNMC member institutions. The group will work collaboratively with churches, businesses, and other organizations interested in building partnerships that address the social, cultural, and economic issues they wish to improve.

Following the training, the group will develop a project that will be implemented to have a positive effect on the neighborhood.

The BNMC and its partners are committed to serving as a catalyst for groups in the neighboring communities that want to identify and change issues facing their community. To learn more about the training and how to participate, contact Ekua Mends-Aidoo at 716.218.7806 for more information.

Training Schedule:

Class 1: Wednesday, Nov. 7th 5-7 p.m.

Class 2: Saturday, Nov. 17th 1:30-3:30 p.m.

Class 3: Thursday, Dec. 6th 5:30-7:30 p.m.

Class 4: Monday, Dec. 17th 5:30-7:30 p.m.

Class 5: Wednesday, Jan. 9th 5:30-7:30 p.m.

Class 6: Wednesday, Jan 23rd 5:30-7:30 p.m.

Class 7: Wednesday, Feb 6th 5:30-7:30 p.m.

Class 8: Wednesday, Feb 20th 5:30-7:30 p.m.

Thereafter, project implementation.

Buffalo-Area Pharmacists Say No to Tobacco Sales in Pharmacies

October 29, 2012 by BNMCin Member Institution(s), News2 Comments

FOR IMMEDIATE RELEASE
October 29, 2012
Contact: Annie Deck-Miller, Senior Media Relations Manager
716-845-8593; annie.deck-miller@roswellpark.org

Buffalo-Area Pharmacists Say No to Tobacco Sales in Pharmacies

BUFFALO — More than 75 percent of Western New York pharmacists say tobacco sales in pharmacies should be legally banned, according to research conducted by Roswell Park Cancer Institute (RPCI) and the University at Buffalo (UB), published in BMC Research Notes. The study found that more than 86% of pharmacists surveyed would prefer to work in a pharmacy that does not sell tobacco products.

The research, led by James Marshall, PhD, Senior Vice President for Cancer Prevention and Population Sciences at RPCI, evaluated the opinions of Western New York pharmacists about the sale of tobacco products in pharmacies and about their role in helping their patients to stop smoking.

“The sale of tobacco products in pharmacies in any locality sends conflicting messages to consumers who visit pharmacies for medication or health products,” said Dr. Marshall. “Pharmacists, dedicated to protecting the health of their customers, recognize tobacco sales as contrary to their professional ethics. They would, in overwhelming numbers, prefer not to be selling cigarettes. This research will inform policymakers and elected officials as they consider regulations of tobacco sales in pharmacies.”

The 2010 survey evaluated opinions of 148 pharmacy mentors from the UB School of Pharmacy and Pharmaceutical Sciences (UBSoPPS) and 345 local supervising pharmacists. Participants were contacted by mail and email. The combined response rate for both surveys was 31%.

The pharmacist’s role in assisting patients to stop smoking also was evaluated. The survey found that more than 75% of pharmacists say they “sometimes” or “rarely/never” ask about tobacco use. The majority of pharmacists also indicate that they are not required to document tobacco use among patients or to enter such information into patient records.

“A striking finding is that pharmacy mentors were more likely than supervising pharmacists to be familiar with patients’ tobacco use and take steps to offer advice and information about how to quit smoking,” said Peter Brody Jr., PharmD, Director of Experiential Education at UBSoPPS. “It was also surprising that area pharmacists seemed not to take full advantage of the opportunity to educate and counsel patients regarding tobacco use. We need to better understand why and do what we can to help correct this issue.”

“This research presents several interesting findings, including that the overwhelming majority of pharmacists would support legislation banning the sale of tobacco in pharmacies,” added Edward Bednarczyk, PharmD, Chair of the Department of Pharmacy Practice at UB. “Importantly, this study also shows a considerable gap between theory and practice, with a substantial majority of pharmacists finding the sale of tobacco in pharmacies inwp-contentropriate, but doing little to prevent the sale or engage patients regarding tobacco use and smoking cessation.”

The study, Tobacco sales in pharmacies: a survey of attitudes, knowledge and beliefs of pharmacists employed in student experiential and other worksites in Western New York,” can be accessed at http://www.biomedcentral.com/1756-0500/5/413/abstract.

Research Shows Effectiveness of New Biomarker to Measure Prostate Tumors

October 23, 2012 by BNMCin Homepage, Member Institution(s), Research9 Comments

New Research Uncovers Promising New Biomarker for Aggressiveness of Prostate CancerRoswell Park-led effort found increased levels of serum glutamate in both primary and metastatic prostate tumors

Research out of Roswell Park Cancer Institute (RPCI) supports the adoption of a new biomarker to measure the aggressiveness of primary prostate tumors. A team of investigators from three institutions, led by Shahriar Koochekpour, MD, PhD, Associate Professor of Cancer Genetics, Urology and Oncology in RPCI’s Department of Cancer Genetics, has for the first time produced data showing that levels of serum glutamate, a naturally occurring nonessential amino acid that plays a key role in cancer metabolism, are increased in patients with primary and metastatic prostate cancer.

Collaborators included James L. Mohler, MD, Gissou Azabdaftari, MD, and Kristopher Attwood, PhD, from RPCI; Robert L. Vessella, PhD, from the University of Washington School of Medicine; and Oliver Sartor, MD, from Tulane Cancer Center and the Tulane University School of Medicine. In a study involving 366 men, the team measured serum glutamate levels in 60 healthy adult males, 197 with primary prostate cancer and 109 with metastatic castration-resistant prostate cancer — cancer that progresses following androgen depletion therapy.

“Comparing normal, primary and metastatic prostate cancer tissues, we discovered that glutamate receptor is expressed at very high levels in primary and metastatic tumors, but at very weak or undetectable levels in benign prostate tissues,” notes Dr. Koochekpour. “And serum glutamate was detected at increased levels proportional to Gleason score, the standard index for rating prostate cancer aggressiveness and prognosis in patients with primary tumors.”

The researchers also demonstrated, for the first time, that glutamate deprivation significantly decreases the growth, migration and invasiveness of prostate cancer cell lines, suggesting potential clinical wp-contentlications. They also report that the glutamate antagonist riluzole (Rilutek), a well-tolerated oral medicine used for mood and anxiety disorders, depression and amyotrophic lateral sclerosis (ALS), induces cell death while inhibiting the progression and motility of human prostate cancer cells.

“We detected one major difference between African-Americans and Caucasians in the study,” Dr. Koochekpour notes. “In African-Americans, serum glutamate levels were higher among those men with metastatic disease than in those with primary prostate cancer, and we didn’t see that trend in Caucasian men. This finding may implicate a role for glutamate metabolism in inter-racial disparities of prostate cancer.”

Dr. Koochekpour and colleagues are currently conducting a preclinical study assessing the effectiveness of riluzole in preventing growth of human prostate cancer cells in animal models, and hope to build on these results in the clinical setting within the next 12-18 months. The paper, “Serum Glutamate Levels Correlate with Gleason Score and Glutamate Blockade Decreases Proliferation, Migration, and Invasion and Induces Apoptosis in Prostate Cancer Cells,” was published October 16 in Clinical Cancer Research and can be accessed at http://clincancerres.aacrjournals.org/content/early/2012/10/10/1078-0432.CCR-12-1308.

Annie Deck-Miller; annie.deck-miller@roswellpark.org; 716-845-8593

BMG is the 1st Physician's Group Outside of Northeast Ohio to Join Quality Alliance

October 19, 2012 by BNMCin Homepage, Member Institution(s), News3 Comments

As one of the oldest and largest multi-specialty physician groups in the state of New York, Buffalo Medical Group, P.C. is the first organization to join the Cleveland Clinic Community Physician Partnership’s Quality Alliance that is outside of northeast Ohio.
Improving the quality of care, the Quality Alliance program couples independent physicians with Cleveland Clinic physicians, aiming to implement thorough and reviewed best practices and evidence-based clinical protocols in order that the best possible care can be given to patients. Cleveland Clinic is an academic medical center that integrates clinical and hospital care with research and education.

The Cleveland Clinic Community Physician Partnership designed the network to bring about the improvement of the quality and consistency of clinical care; reduce costs and increase efficiency; and provide access to expertise, data and experience. The alliance meets these goals through physician-led review of patient care, physician-developed clinical protocols, mechanisms assuring adherence to those protocols, and common data collection and reports. With over 900 independent physician members, the Alliance is one of the third largest networks in the nation of its kind striving to standardize and improve the quality of care.

“Partnering with the Cleveland Clinic Community Physician Partnership and Quality Alliance is a logical extension of BMG’s commitment to providing exemplary care for our patients” said Irene S. Snow. M.D., Medical Director of the BMG.

Chief Medical Officer of Cleveland Clinic’s Community Physician Partnership & Quality Alliance, Tarek Elsawy, M.D., stated that “The Buffalo Medical Group is the right type of partner, as it has demonstrated through its highly engaged culture of quality and commitment to process improvement.”

BMG is committed to providing the best comprehensive care for patients, having achieved the highest level of recognition by the National Committee for Quality Assurance for Patient Centered Medical Home – the first health care provider in WNY to do so. BMG has also been recognized for its care for diabetes patients by the same committee. BMG adds more than 100 primary care, specialty care and sub-specialty physicians to the program.

'Know Your Stats' Promotes Prostate Cancer Screening for 2nd Year

October 15, 2012 by BNMCin Community, Event, Member Institution(s), WellnessLeave a Comment

Roswell Park, Buffalo Bills Team up on ‘Know Your Stats’ Awareness Campaign for Second YearAmerica’s first cancer center, Bills partner to host prostate cancer screening clinic at Ralph Wilson Stadium

One in six men will be diagnosed with prostate cancer, but with early detection, about 90 percent of these cancers will be cured. Roswell Park Cancer Institute (RPCI) and the Buffalo Bills are encouraging men over 50, or those 40 and over with risk factors such as a family history of the disease, to get informed about prostate cancer and talk with their doctor about whether early detection is right for them.

For the second consecutive year, RPCI and the Bills are hosting the Prostate Cancer Early Diagnosis Outreach Clinic, a free prostate cancer education and screening event, in connection with the American Urological Association Foundation’s Know Your Stats about Prostate Cancer® campaign. RPCI doctors will be performing free screenings that will include prostate-specific antigen (PSA) blood tests and digital rectal exams (DRE) for eligible men at the event on Tuesday, October 23rd from 4:30 p.m. to 7 p.m. at the Ralph Wilson Stadium located at 1 Bills Drive in Orchard Park.

Special wp-contentearances will be made throughout the event by the Buffalo Jills, Buffalo Bills alumni and Buffalo Bills Wide Receiver David Nelson. Tours of Ralph Wilson Stadium will be offered for attendees, who will also be eligible to win raffle prizes.

Men planning to attend the clinic should call 1-877-ASK-RPCI (1-877-275-7724) or complete the online registration form at http://www.roswellpark.org/knowyourstats. From that site, visitors can also access ads featuring Bills wide receiver David Nelson, whose father is a prostate cancer survivor.

Light-A-Life 2012 Gives the Gift of Remembrance

October 11, 2012 by BNMCin Campus-wide, Community, Fundraiser, Member Institution(s)Leave a Comment

A great way for families to memorialize a loved one that they have lost.

Every year, the holiday season presents an opportunity to give gifts to our loved ones and to those we may not even know. While the holiday season ignites feelings of charity, love, food, and family, nostalgia often arises when it is time to make new memories in the midst of remembering those of old.

The Hospice Foundation of Western New York gives individuals and families the opportunity to memorialize loved ones during the holiday season. In its 24th year, the annual Light-A-Life fundraiser serves to honor lost loved ones and to assist with the care of patients within Hospice Buffalo. Helping to keep memories alive and provide the best care for individuals with serious end-of-life illnesses, the Hospice Foundation is shooting for a $120,000 goal this year. With the overwhelming support of family and friends last year, gifts in 2011 reached $117,000. By remembering your loved one, you can help the Hospice Foundation reach this year’s goal to support patients in hospice care.

The Light-A-Life commemorative bells will be given to supporters who give a gift of $55. The porcelain bells are the 18th in a collectible series that can be remembered for future generations. The hand-painted bells by Buffalo ceramic artist Becky Plummer of Barking Spider Pottery will have your loved one’s name inscribed in the inside by a dedicated Hospice volunteer. The traditional Light-A-Life Memorial Tree lighting event will take place on Saturday, December 1st. The trees will be adorned with red, silver, gold and green bows and tags with loved ones’ names on them. The event is free and open to the public.

Additional gift levels include:

Did you know that Hospice Buffalo is the only licensed hospice program in Erie County? Hospice Buffalo places an emphasis on offering the best quality of life services to patients enduring end-of-life illnesses. Patients are guaranteed to receive holistic care that not only caters to physical needs, but to the social, psychological, emotional and spiritual needs of the patient as well. With the help of its team of doctors, nurses, social workers, spiritual advisors, and volunteers, Hospice Buffalo serves the patient and their family members, helping each to live their best lives.

To give the gift of life and honor your loved one, please visit www.community.hospicebuffalo.com/lal2012-support

Cuomo Seeks to Boost Organ and Tissue Donations in NYS with Lauren's Law

October 8, 2012 by BNMCin Homepage, Member Institution(s), NewsLeave a Comment

With the help of Unyts, one the leading procurement organizations in the nation, Western New York has one of the highest organ and tissue consent rates in the country. New York State, though, is the 3rd state with the lowest consent rates for organ and tissue donations in the U.S. With 113,000 people on the national waiting list for organ and tissue donations, 9,700 of them are residents of New York State, yet, the Empire State only has 18% of its adults registered as donors. The national average is 43%.
Beginning in October 2013, the number of New York State residents who become organ and tissue donors is expected to increase based on new language on the New York State Department of Motor Vehicles driver’s license wp-contentlication. A new bill signed into legislation by Governor Andrew Cuomo, called “Lauren’s Law,” requires wp-contentlicants to check one of the two options for organ donor registration. Applicants can either check “yes” or “skip this question” under the organ registration section.

Back in June, Lauren’s Law was passed by unanimous vote by the New York State Assembly and Senate. Governor Cuomo stated that “By adding this new language to DMV wp-contentlication forms, it is our hope that many more New Yorkers sign up to be on the list of those willing to donate an organ or tissue.” Cuomo recognized Senator David Carlucci (D-Rockland/Orange) and Assemblyman Felix Ortiz (D-Brooklyn) for their efforts to support the passing of the bill into law along with advocate Lauren Shields.

The President and CEO of Unyts, Mark Simon said that “[The bill] will result in increased donations and more opportunities for life safe and life enhancing transplants.”

Lauren Shields, who is now a 12 year old girl, received a heart transplant back in 2009. Officials named the law Lauren’s Law as a result of Shields’ advocacy efforts to help save lives by organ and tissue donations. Shields is a resident of Stony Point in Rockland County. She began her battle with heart failure when she was 9 years old, diagnosed with viral myocarditis (inflammation of the heart muscle), an illness preventing her heart from being able to pump blood through her body because it was so swollen. Today, as a recipient of a successful transplant and a healthy child, Shields aspires to become a cardiologist to help save lives.

For more about Shields’ story, watch the video below:

“I never want anyone to have to wait for a transplant like I did.” -Lauren Shields

To learn how to register and become a donor and help save a life, please visit www.unyts.org/get-involved/donor-registry/.

UB Ranked One of the World’s Best Universities by Times Higher Education

October 3, 2012 by BNMCin Homepage, Member Institution(s), NewsLeave a Comment

UB Ranked One of the World’s Best Universities by Times Higher Education

Times Higher Education has named the University at Buffalo as one of the world’s top 200 universities.

UB is ranked 198th in the 2012-13 Times Higher Education World University Rankings, up from last year’s ranking among the top 201 to 225 universities worldwide. The assessment uses 13 performance indicators to analyze how well a university is doing in core missions including teaching, research, knowledge transfer and international outlook.

“This is very good news. Moving into the top-200 will enhance UB’s already-strong reputation overseas and help us attract outstanding students from around the world,” said Stephen C. Dunnett, PhD, UB professor and vice provost for international education.

“International students are particularly conscious of university rankings, and UB’s steady ascent in various international rankings in recent years — a reflection of our strong institutional commitment to excellence — is certainly well recognized and wp-contentreciated by students and their families overseas.”

Times Higher Education is a leading higher education magazine, and the recognition of UB as a top-200 university demonstrates UB’s growing global reputation. The data for the rankings were collected by Thomson Reuters, which considered about 700 institutions in 69 countries.

In recent years, UB has invested in recruiting additional high-quality faculty, attracting researchers from around the world to Western New York. These faculty members conduct research on some of the world’s most pressing problems, and provide students with an excellent education in the classroom.

Under President Satish K. Tripathi, UB has embarked on the next phase of its UB 2020 plan for academic excellence. With the support of the NYSUNY 2020 legislation, signed into law last year by Gov. Andrew M. Cuomo, UB is in the midst of a historic transformation. The university is hiring 250 new faculty over the next five years, offering new programs to enrich students’ academic experiences and opening new facilities on its three campuses, with the goal of becoming one the world’s leading public research universities and increasing its regional economic impact.

Abroad, the university has cultivated relationships with distinguished educational institutions throughout the world, cooperating with international partners on student exchanges, joint research projects and the delivery of degree programs overseas.

At home, UB consistently places in the top 20 in the United States for international student enrollment, according to annual data published by the Institute of International Education. In 2010-11, for instance, UB had 5,185 foreign students, the 17th largest population in the nation.

John DellaContrada; dellacon@buffalo.edu; 716-645-4601

UB Department of Medicine Names New Chief of Nephrology Division

October 1, 2012 by BNMCin Member Institution(s), NewsLeave a Comment

Release Date: October 1, 2012Contact: Ellen Goldbaum, goldbaum@buffalo.edu
University at Buffalo
716-645-4605

UB Department of Medicine Names New Chief of Nephrology Division

BUFFALO, N.Y. — Richard J. Quigg Jr., MD, professor of medicine at the University of Chicago and former chief of its nephrology section, has been named the inaugural Arthur M. Morris Chair in Nephrology and chief of the division of Nephrology in the Department of Medicine in the University at Buffalo School of Medicine and Biomedical Sciences.

A photo of Quigg is at http://www.buffalo.edu/news/13714.

The announcement was made by Anne B. Curtis, MD, Charles and Mary Bauer Professor and chair of the Department of Medicine in UB’s School of Medicine and Biomedical Sciences.

The primary focus of Quigg’s research laboratory is to identify pathogenic mechanisms that underlie kidney disease. He is nationally and internationally renowned for his research into diseases of the glomeruli. Glomerular diseases damage the clusters of blood vessels called glomeruli, which filter blood in the kidneys, letting protein and sometimes red blood cells leaks into the urine, ultimately interfering with proper kidney function.

Quigg’s research interests include the role of the complement system, a major factor in the body’s immune response and other defenses, in glomerular disease, lupus nephritis, and diabetic nephropathy. He uses a variety of contemporary techniques to investigate disease pathogenesis and to identify sites of potential therapeutic manipulation. In addition to using animal models, his lab is involved in clinical studies examining the role of the complement system in various kidney diseases and examining gene profiles from renal tissue obtained from patients with these conditions.

Quigg received his undergraduate and medical degrees from Boston University. He completed his medical residency at SUNY Stony Brook and research and clinical fellowships in nephrology at the Boston University Medical Center. He was wp-contentointed to the University of Chicago in 1994 as an associate professor, and was promoted to professor in 2001. He served as chief of the Section of Nephrology at the university and was director of its Functional Genomics Facility. Before joining the University of Chicago, he was an assistant professor at the Medical College of Virginia.

Investigational Brain Cancer Vaccine to Be Tested in Phase I Roswell Park Study

September 27, 2012 by BNMCin Member Institution(s), News, ResearchLeave a Comment

FOR IMMEDIATE RELEASESeptember 27, 2012
Contact: Annie Deck-Miller, Senior Media Relations Manager
716-845-8593; annie.deck-miller@roswellpark.org

Investigational Brain Cancer Vaccine to Be Tested in Phase I Roswell Park Study
Peptide vaccine targets cancer survival protein, putting tumor cells in a Catch 22

BUFFALO — A new clinical research study at Roswell Park Cancer Institute (RPCI) will test a first-of-its-kind cancer “vaccine” that may prove effective against many forms of solid-tumor cancers. The vaccine, to be investigated in a trial involving patients with brain cancer, generates an immune response that wp-contentears to put the target molecule, the cancer survival protein survivin, into a bind it can’t escape.

The peptide vaccine, developed at Roswell Park by Robert Fenstermaker, MD, and Michael Ciesielski, PhD, is based upon a specially engineered small protein molecule called a “peptide mimic.” Dr. Fenstermaker is principal investigator of the phase I clinical research study, which will test the safety and immunological effects of the vaccine in patients with two types of brain cancer: glioblastoma multiforme (GBM) and anaplastic glioma. Called SurVaxM, the injectable vaccine will initially be given in four doses to nine patients.

Survivin, produced by at least 80% of cancers, is a protein that helps cancer cells to survive under stressful conditions. It is present only in diseased cells, which are caught in an unwinnable situation when exposed to the vaccine.

“SurVaxM puts cancer cells in a Catch 22,” says Dr. Fenstermaker, who is Chair of RPCI’s Department of Neurosurgery and Director of the Institute’s Neuro-Oncology Program. “The vaccine kills tumor cells that express survivin. If the cells turn survivin off to escape the vaccine, they’re essentially committing suicide.”

The engineered peptide used in the vaccine is able to stimulate an immune response because the cancer recognizes it as a foreign molecule.

“We arrived at this peptide through reverse immunology,” notes Dr. Ciesielski. “We knew we wanted to target survivin because it is expressed by so many tumors. We looked at many survivin peptides trying to find the best one to use as our vaccine. Once we identified one that looked promising, we engineered it to be more potent and produce a better response by enlisting multiple arms of the immune system.”

In preclinical studies, the vaccine was effective against several cancers, including gliomas and prostate, ovarian, breast and kidney tumors that produce survivin. Studies in which human glioma, lymphoma and leukemia cells were exposed to the vaccine outside the body also produced a strong response. “In those earlier studies, the response was persistent,” Dr. Ciesielski says. “It wp-contentears that the vaccine continues to provide lasting immunity after the tumor has been eliminated.”

Roughly 15,000 people are newly diagnosed with glioblastomas and anaplastic gliomas in the U.S. every year. These cancers are very difficult to treat, and are often fatal.

“Survival rates for malignant gliomas have improved modestly over the last two decades, but better therapies are desperately needed,” Dr. Fenstermaker says. “We’re anxious to move ahead with this study and, hopefully, go on to larger studies in the years ahead, but we first have to show that this is a safe and well-tolerated drug for a group of terrible diseases.”

Because they enlist the body’s own cells to fight cancer, immune-based therapies generally have few adverse side effects. The trial is the fourth clinical research study launched through RPCI’s Center for Immunotherapy this year.

The study is National Cancer Institute trial no. NCT01250470. For more information about SurVaxM and this new phase I research study, call 1-877-ASK-RPCI (1-877-275-7724) or email askrpci@roswellpark.org.

Ciesielski and Fenstermaker credit early seed funding from donations with helping to move their research forward and generating additional dollars in new grant funding from organizations such as the National Institutes of Health/National Cancer Institute (R21 NS049309-01) and the American Cancer Society. Additional support from The Jayne and Phil Hubbell Family was instrumental in advancing the team’s research.

-30-

Editor’s note: Photo caption: Robert Fenstermaker, MD, left, and Michael Ciesielski, PhD. Video interview with Drs. Fenstermaker and Ciesielski available at https://vimeo.com/48443468. For additional photos and multimedia, including B-roll video, send request to: annie.deck-miller@roswellpark.org.

Landmark Gift From Oishei Foundation for Children's Hospital

September 25, 2012 by BNMCin Member Institution(s), NewsLeave a Comment

A $10 million donation to Kaleida Health means the brand new hospital will be named the John R. Oishei Children’s Hospital, continuing to serve the women and children of Buffalo. The donor, The John R. Oishei Foundation, named the facility after the late industrialist and philanthropist, John R. Oishei, who established the Foundation in 1940.
Jim Wadsworth, Chairman of the Foundation stated that “The primary reason [Oishei] began his philanthropy back in the 1940s was to benefit the children of his employees and of the community.” The mission of the Foundation is “to be a catalyst for change to enhance economic vitality and the quality of life for the Buffalo Niagara region.”

The unprecedented gift will enable the hospital to continue expanding the specialized health care services offered to its infant and women patients. The 430,000 sq. ft., 12-story facility will house a state-of-the-art Neonatal Intensive Care Unit which received a $2 million gift in August, a connected ambulatory care center, and a family resource center. In the future, plans include a Women’s Pavilion to house labor and delivery, post partum care, the regional perinatal center for high-risk pregnancies, and a women’s health center providing prenatal and gynecological care.

“Similar to how John R. Oishei sought the best technology available in his time to create the first automobile wiper blades and ultimately the Trico Products Corporation, the Foundation that now bears his name and legacy will share its resources to make advanced technologies and care available today to improve the health and lives of families throughout our community,” said James R. Kaskie, President and Chief Executive Officer of Kaleida Health.

Set to open in 2016, the John R. Oishei Children’s Hospital will sit on the corner of High and Ellicott Streets, across from the Buffalo General Medical Center.

Read more coverage about the gift below:

Oishei Gift Boosts Medical Campus

Oishei Makes $10M Pledge to New Children’s Hospital

Oishei Foundation Gives Hospital $10M

New Oishei Children’s Hospital Receives $10 Million Gift

Oishei Gifts $10 Million Towards New Children’s Hospital